Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib alone or in combination with everolimus in unresectable hepatocellular carcinoma
2009-011884-35Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Sorafenib monotherapy with Sorafenib + everolimus combination (2 arms). Primary endpoint: Progression-free at 12 weeks. Started Nov 2009; status: completed.
02
Drugs
sorafenibeverolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-011884-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011884-35.